Universitaetsklinikum Heidelberg AöR

Clinical research spans colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, pancreatic ductal adenocarcinoma, and rare sarcomas such as synovial sarcoma and desmoplastic small round cell tumor.

• Neoadjuvant treatment
• Adjuvant chemotherapy
• Targeted antibody-drug conjugates
• Biomarker-guided therapy

Trials in this area also address treatment selection around surgery and resistance to systemic therapy.

The sponsor supports research in glioblastoma, WHO grade 2 or 3 glioma, pediatric low-grade glioma, and other high-risk pediatric malignancies, including tumors with aggressive molecular features.

• Perioperative therapy
• Progressive glioma
• Immune-based combinations
• Childhood and adolescent oncology

Work in this field also includes outcomes related to neuropsychologic development and disease control in early-life neuro-oncologic conditions.

Additional studies address cystic fibrosis, tuberous sclerosis complex, adrenal insufficiency, acromegaly, Takotsubo syndrome, and acute ischemic stroke, alongside other immune-mediated and endocrine conditions.

• Inflammation-related treatment
• Endocrine disorders
• Neurologic and cardiac injury
• Rare disease management

These trials include interest in myocardial injury, lung function, and metabolic disease across specialized patient groups.

The research portfolio also includes healthy volunteer studies and translational work on pharmacokinetics, microbiome interactions, and immune profiling relevant to oncology and other therapeutic areas.

• Drug disposition
• Immune signature analysis
• Microbiome-related effects
• Therapeutic response prediction

These studies support investigation of treatment response, exposure, and biologic variation across clinical settings.